|1.||Stringer, Bradley: 4 articles (04/2011 - 03/2007)|
|2.||Bowman, Douglas: 4 articles (02/2011 - 06/2007)|
|3.||Ecsedy, Jeffrey A: 4 articles (02/2011 - 03/2007)|
|4.||Danaee, Hadi: 3 articles (04/2011 - 10/2010)|
|5.||Liu, Hua: 3 articles (04/2011 - 10/2010)|
|6.||Ecsedy, Jeffrey: 3 articles (04/2011 - 11/2008)|
|7.||Galvin, Katherine: 3 articles (04/2011 - 06/2007)|
|8.||Shinde, Vaishali: 3 articles (02/2011 - 06/2007)|
|9.||Chakravarty, Arijit: 3 articles (02/2011 - 06/2007)|
|10.||Zhang, Mengkun: 3 articles (02/2011 - 03/2007)|
11/01/2012 - "Among them, MLN8054 has been proved to be a selective Aurora-A inhibitor, and is currently being evaluated in a phase I trial for patients with advanced solid tumors. "
04/01/2011 - "In vivo, treatment of ATC by MLN8054 resulted in an up to 86% reduced tumor volume and 89% reduced tumor vascularity. "
02/01/2011 - "Together, these new pharmacodynamic assays provide evidence for Aurora A inhibition by MLN8054 in patient skin and tumor tissues."
02/01/2011 - "Patients with advanced solid tumors received MLN8054 orally for 7 consecutive days in escalating dose cohorts, with skin and tumor biopsies obtained before and after dosing. "
10/01/2010 - "Patients with advanced solid tumors received increasing doses of MLN8054 in 28-day cycles until dose-limiting toxicity (DLT) was seen in ≥2 of 3-6 patients in a cohort. "
|2.||Prostatic Neoplasms (Prostate Cancer)
07/15/2011 - "This warrants the clinical development of MLN8054 with radiation for prostate cancer patients."
07/15/2011 - "MLN8054, a novel small molecule Aurora-A inhibitor showed radiation sensitization in androgen-insensitive prostate cancer in vitro and in vivo. "
07/15/2011 - "In vitro inhibition of Aurora-A by MLN8054 sensitized prostate cancer cells, as determined by dose enhancement ratios in clonogenic assays. "
07/15/2011 - "In vitro studies consisted of culturing PC3 and DU145 prostate cancer cells and then immunoblotting Aurora A and phospho-Aurora A after radiation and/or nocodazole with MLN8054. "
07/15/2011 - "To determine whether MLN8054, an Aurora kinase A (Aurora-A) inhibitor causes radiosensitization in androgen-insensitive prostate cancer cells in vitro and in vivo. "
06/01/2007 - "In this study, we delineate the sequence of events that lead to aneuploidy following Aurora A inhibition using MLN8054, a selective Aurora A small-molecule inhibitor. "
06/01/2007 - "Consistent with the chromosome segregation defects, cells treated with MLN8054 develop aneuploidy over time. "
06/01/2007 - "MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy."
|4.||Melanoma (Melanoma, Malignant)
02/01/2015 - "Furthermore, AurkA inhibition, by exposure of melanoma cells to MLN8054, a specific AurKA inhibitor, induced apoptosis in both melanoma cell lines and molecular alterations in the IPA-identified molecular pathway. "
01/01/2014 - "A human melanoma cell line with the B-RAF (V600E) mutation (A375mel) was exposed to B-RAF inhibitor (GSK2118436), MEK inhibitor (GSK1120212) and AurkA inhibitor (MLN8054) as single agents or in various combinations (BRAF plus AurkA inhibitor, MEK plus AurkA inhibitor or triple combination BRAF plus MEK plus AurkA inhibitor). "
01/01/2013 - "Here, using a mouse model with orthotopic implantation of metastatic melanoma tumours taken from 19 patients, we observed that targeting aurora kinases with MLN8054/MLN8237 impaired mitosis, induced senescence and markedly blocked proliferation in patient tumour implants. "
|5.||Thyroid Neoplasms (Thyroid Cancer)
|1.||aurora kinase (aurora A kinase)
|3.||Biological Markers (Surrogate Marker)
|4.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|5.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|6.||Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
|7.||von Willebrand Factor
|8.||Epidermal Growth Factor (EGF)
|10.||2- ((3- ((4- ((5- (2- ((3- fluorophenyl)amino)- 2- oxoethyl)- 1H- pyrazol- 3- yl)amino)quinazolin- 7- yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate
|1.||Heterologous Transplantation (Xenotransplantation)